<DOC>
	<DOCNO>NCT00929331</DOCNO>
	<brief_summary>This study design test safety immunogenicity Fluviral® ( 2009 - 2010 Season ) adult age 18 60 year 60 year .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study Fluviral® ( 2009 - 2010 Season ) Adults Aged 18 60 Years Over 60 Years</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject Male female adult , 18 60 year age 60 year age . Satisfactory baseline medical assessment history physical examination Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Participation previous year 's ( 2008 ) Fluviral® registration study Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) /product ( ) within 30 day precede first dose study vaccine/product , plan use study period . Acute disease time enrollment . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e . oral temperature &lt; 38.0°C . Significant acute chronic , uncontrolled medical psychiatric illness . `` Uncontrolled '' define : Requiring institution new medical surgical treatment within one ( 1 ) month prior study enrollment , Requiring reinstitution previously discontinue medication medical treatment within one month prior study enrollment , Requiring change medication dosage one month prior study enrollment due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) , Hospitalization event fulfil definition SAE within one month prior study enrollment . • Any confirm suspected immunosuppressive condition include : History human immunodeficiency virus ( HIV ) infection , Cancer treatment cancer , within 3 year study enrollment . Persons history cancer diseasefree without treatment 3 year eligible . History renal impairment . History hepatic dysfunction due hepatitis B , C toxins include alcohol . Complicated insulindependent diabetes mellitus . Unstable cardiopulmonary disease require chronic medical therapy associate functional impairment . Presence blood dyscrasia , include hemoglobinopathy myelo lymphoproliferative disorder . Receipt systemic glucocorticoid within 1 month study enrollment , cytotoxic immunosuppressive drug within six month study enrollment . Inhaled topical steroid allow . A history demyelinate disease include Multiple Sclerosis GuillainBarré syndrome . Presence active neurological disorder . History chronic alcohol consumption and/or drug abuse . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g . lowdose aspirin , without clinicallyapparent bleeding tendency eligible . Receipt influenza vaccine within 6 month prior study enrollment . Administration vaccine within 30 day prior study enrollment study period . Subjects receive treatment enrollment follow per protocol include safety analysis , exclude accordingtoprotocol cohort . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan study . Any known suspected allergy constituent Fluviral® and/or history anaphylactic type reaction constituent vaccine . A history severe adverse reaction previous influenza vaccination . Lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Fluviral®</keyword>
</DOC>